Entresto’s reimb for HFrEF is extended again
By Eo, Yun-Ho | translator Kim, Jung-Ju
23.06.25 18:38:11
가나다라
0
Positions itself at the same level as an ACE inhibitor in patients with LVEF below 40%
Strengthens its position as a first-line therapy after solidifying its position as a treatment for hospitalized patients
According to industry sources, the reimbursement standards for Entresto (sacubitril) will be revised starting next month (July) to cover its use in combination with standard therapy (beta blockers, aldosterone antagonist, etc.) in patients with chronic heart failure with reduced ejection fraction whose left ventricular ejection fraction (LVEF) is below 40%.
This is an extension from the previous reimbursement standard that was limited to ‘patients who have been receiving stable dose for over 4 weeks,’ and also an
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)